Remdesivir News and Research

RSS

Remdesivir protects kidney and heart health in transplant recipients

Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later, according to findings from a target trial emulation study that published in JAMA Network Open.

28 Jul 2026

Animal-free lung model unlocks better treatments for RSV in babies

Future therapies for respiratory syncytial virus (RSV) must target both the virus and its immune response to ensure babies get the best possible outcomes, finds a new study by researchers at UCL and Great Ormond Street Hospital for Children (GOSH).

13 Jul 2026

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

3 Jul 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

Atomic-level images could improve future COVID-19 antiviral drug design

The closest-ever detailed look at a key enzyme inside the virus that causes COVID-19 could lead to more effective treatment of the disease.

10 May 2026

Global Virus Network outlines priorities as Marburg virus emerges in Ethiopia

The Global Virus Network (GVN), a coalition of leading human and animal virologists in more than 40 countries dedicated to advancing pandemic preparedness through research, education and training, and global health solutions, today issued a statement on the newly confirmed outbreak of Marburg virus disease (MVD) in southern Ethiopia.

27 Nov 2025

Multicenter study supports cautious use of low-dose HCQ in severe COVID-19 cases

This multicenter study investigates the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients in China, aiming to clarify conflicting evidence from prior research.

7 Jul 2025

New COVID variant NB.1.8.1 spreads across continents amid calls for vigilance

The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January 2025 and has rapidly spread across Asia and into other regions, including parts of the United States.

6 Jun 2025

Breakthrough bat organoid platform sheds light on behavior of zoonotic viruses

Did you know that more than 75% of new infectious diseases affecting humans originally come from animals? Bats, in particular, are natural hosts to some of the world's most dangerous viruses, including those responsible for COVID-19 (SARS-CoV-2), MERS-CoV, influenza A, and hantavirus outbreaks.

15 May 2025

Researchers develop drug cocktail to target enteroviruses

Enteroviruses are a group of viruses that cause everything from the common cold to meningitis, polio, type 1 diabetes, and much more. Over 100 different types have been described by researchers, and millions of people are infected each year.

15 Apr 2025

New quinoline-based antiviral shows strong promise against SARS-CoV-2

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

10 Apr 2025

In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domain

Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, resulting in the coronavirus disease 2019 (COVID-19) pandemic.

4 Feb 2025

Antidepressant fluoxetine found ineffective for early COVID-19 treatment

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

22 Jan 2025

Psilocybin helps reduce depression in clinicians amid COVID-19 crisis

Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021.

5 Dec 2024

Chemical genetics uncovers promising anti-COVID compounds

This new article publication from Acta Pharmaceutica Sinica B, discusses the identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics.

25 Sep 2024

Human challenge study reveals lasting cognitive decline after mild COVID-19

Researchers from the UK conducted the first human challenge study of SARS-CoV-2, revealing long-lasting cognitive deficits in unvaccinated participants infected with the virus, especially in memory and executive function.

23 Sep 2024

Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

18 Sep 2024

Cardiovascular risks of COVID-19 antivirals

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.

16 Sep 2024

COVID-19 treatment reporting in U.S. media lacked scientific rigor, study says

A study in JMIR Infodemiology reveals how U.S. media reports on early COVID-19 therapies often lacked scientific evidence and highlighted uncertainties, contributing to misinformation and public mistrust.

2 Sep 2024

Research highlights media misrepresentation of COVID-19 drug efficacy

A new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and the uncertainty surrounding three unproven therapeutics were portrayed by the U.S. news media during the early days of the COVID-19 pandemic.

30 Aug 2024